Betta Pharmaceuticals Co., Ltd.

Jacobio Pharmaceuticals Co., Ltd.

Shaojing Hu

Wei Long

Fei Wang

Yinxiang Wang

Yanping Wang

Lieming Ding

Cunbo Ma

Fenlai Tan

Lei Zhang

Tong Wu

Yunyan Hu

Hong Cao

Mingming Chen

Guiqun Yang

Xiangyong Liu

Xiaoyan Shen

Qinglong Li

Jinlong Bai

Yuelei Du

Haiquan Fang

Zhiguo Xu

Xiangdong Zhao

Di Kang

Panliang Gao

Zongquan Li

Liufeng Zhou

Xinping Wu

Huifeng Han

Zilong Xu

Shujun Yuan

Disclosed are tricyclic compounds as bromodomain and extra-terminal (BET) inhibitors which are shown as formula I, their synthesis and their use for treating diseases. More particularly, disclosed are fused heterocyclic derivatives useful as inhibitors of BET, methods for producing such compounds and methods for treating diseases and conditions wherein inhibition of one or more BET bromodomains provides a benefit.

Tricyclic compounds

Disclosed are tricyclic compounds as bromodomain and extra-terminal (BET) inhibitors which are shown as formula I, their synthesis and their use for treating diseases. More particularly, disclosed are fused heterocyclic derivatives useful as inhibitors of BET, methods for producing such compounds and methods for treating diseases and conditions wherein inhibition of one or more BET bromodomains provides a benefit. 

This invention relates to certain novel pyrazine derivatives (Formula I) as SHP2 inhibitors which is shown as formula I, their synthesis and their use for treating a SHP2 mediated disorder. More particularly, this invention is directed to fused heterocyclic group derivatives useful as inhibitors of SHP2, methods for producing such compounds and methods for treating a SHP2-mediated disorder. 

Heterocyclic derivatives useful as SHP2 inhibitors

The compound of Formula I, the crystalline form thereof, and methods of preparing and using them are provided. 

Crystalline form of fused pyridine derivative's maleate and uses thereof

Heterocyclic pyrimidine compounds that modulate mutant-selective epidermal growth factor receptor (EGFR) and ALK kinase activity are disclosed. More specifically, the invention provides pyrimidines which inhibit, regulate and/or modulate kinase receptor, particularly in selectively modulation of various EGFR mutant activity and ALK kinase activity have been disclosed. Pharmaceutical compositions comprising the pyrimidine derivative, and methods of treatment for diseases associated with protein kinase enzymatic activity, particularly EGFR or ALK kinase activity including non-small cell lung cancer comprising administration of the pyrimidine derivative are disclosed.

Protein tyrosine kinase modulators and methods of use

Disclosed is Icotinib phosphate (i.e., the compound of Formula (I)) and polymorph forms thereof, and methods of preparing and using them. 

Polymorphic forms of icotinib phosphate and uses thereof

This invention relates to novel fused quinazoline derivatives of Formula I as c-Met inhibitors, their synthesis and uses for treating c-Met mediated disorders. 

Fused pyridine derivatives useful as c-Met tyrosine kinase inhibitors

The present invention relates to the polymorphic forms of the compound of Formula I, preparation thereof and pharmaceutical compositions, and use of a polymorph above in the treatment of a disease, a disorder or a condition, or in the manufacturing of a medicament for the treatment of a disease, a disorder or a condition. 

Polymorphic forms of icotinib and uses thereof

Provided are Icotinib maleate (the compound of Formula I) and polymorph forms thereof, and methods of preparing and using them. 

Polymorphic forms of icotinib maleate and uses thereof

The present invention relates to novel analogs of glucagon like peptide and compositions that are useful for up-regulating insulin expression in mammals and for treating diabetes. In particular, these peptide derivatives have a peptide mimic linker and provides long duration of action for the treatment of diabetes and other insulinotropic peptide related diseases, gastrointestinal function and activities associated with glucagon levels.

Glucagon like peptide analogs, composition, and method of use

This invention relates to certain novel fused quinazoline derivatives (Formula I) as c-Met inhibitors which is shown as formula I, their synthesis and their use for treating a c-Met mediated disorder. More particularly, this invention is directed to fused heterocyclic derivatives useful inhibitors of c-Met, methods for producing such compounds and methods for treating as c-Met mediated disorder 

Substituted fused heterocycles as c-Met tyrosine kinase inhibitors

The present invention relates to the technical field of medicine, and specifically provides methods for preparing Icotinib, Icotinib hydrochloride, and intermediates thereof. These methods avoid the use of phosphorus oxychloride, thereby greatly reducing the emission of pollutants, which is of major benefits to the economy and environment.

Methods of preparing icotinib and icotinib hydrochloride, and intermediates thereof

Provided is a glucagon-like peptide-1 (GLP-1) analog shown as the following formula, wherein X is selected from glycine and glycinamide. The GLP-1 analog has a non-proteogenic amino acid residue in position 8 relative to the sequence GLP-1, and is acylated with a moiety comprising two acidic groups to the lysine residue in position 26. The GLP-1 analog is resistant to dipeptidyl peptidase IV so as to have an extended half-life in vivo. Also provided is a use of the GLP-1 analog in conquering blood sugar. 

Growing community of inventors

Beijing, China

Shaojing Hu